NCT07396324 RECRUITING Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
RenJi Hospital
NCT04584255 ACTIVE NOT RECRUITING Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
NCT07581834 RECRUITING Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Fujian Cancer Hospital
NCT07288359 RECRUITING Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01042379 RECRUITING I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
QuantumLeap Healthcare Collaborative
NCT07570966 NOT YET RECRUITING Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis Pharmaceuticals
NCT06998407 RECRUITING ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Avenzo Therapeutics, Inc.
NCT07558733 RECRUITING Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Faeth Therapeutics
NCT07539753 NOT YET RECRUITING Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
Nanfang Hospital, Southern Medical University
NCT06726148 RECRUITING Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis Pharmaceuticals
NCT05982093 RECRUITING Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
SOLTI Breast Cancer Research Group
NCT05455619 RECRUITING Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
SynDevRx, Inc.
NCT04606446 RECRUITING Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Pfizer
NCT07198724 RECRUITING ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Sarah Sammons, MD
NCT05467891 RECRUITING Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Oana Danciu
NCT06649331 RECRUITING Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Fudan University
NCT05660083 RECRUITING Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
The Methodist Hospital Research Institute
NCT07483307 RECRUITING A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06590857 ACTIVE NOT RECRUITING Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
RayzeBio, Inc.
NCT04585750 RECRUITING The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
NCT07466927 NOT YET RECRUITING Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
Fudan University
NCT05524584 RECRUITING Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
NCT05546268 ACTIVE NOT RECRUITING Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics, Inc
NCT07426822 NOT YET RECRUITING Rash & Diarrhea Prophylaxis With Capivasertib
Maryam Lustberg
NCT05383196 ACTIVE NOT RECRUITING Onvansertib + Paclitaxel In TNBC
Antonio Giordano, MD
NCT06064812 RECRUITING A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Forward Pharmaceuticals Co., Ltd.
NCT07396454 RECRUITING Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
The First Affiliated Hospital with Nanjing Medical University
NCT04573231 RECRUITING Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
University of Wisconsin, Madison
NCT07367178 NOT YET RECRUITING Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer
MedSIR
NCT05305924 RECRUITING Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
The Methodist Hospital Research Institute
NCT07366112 NOT YET RECRUITING CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
Peking University People's Hospital
NCT07222215 RECRUITING PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT06518837 RECRUITING Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Rutgers, The State University of New Jersey
NCT06970912 RECRUITING ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Peking University People's Hospital
NCT04448886 ACTIVE NOT RECRUITING Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Ana C Garrido-Castro, MD
NCT06334432 ACTIVE NOT RECRUITING Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
NCT05826964 ACTIVE NOT RECRUITING Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
NCT06351332 ACTIVE NOT RECRUITING ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Filipa Lynce, MD
NCT07235176 RECRUITING Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Qilu Pharmaceutical Co., Ltd.
NCT06967103 RECRUITING QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Henan Cancer Hospital
NCT05150652 ACTIVE NOT RECRUITING Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Irada Ibrahim-zada
NCT04762979 ACTIVE NOT RECRUITING Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Marina N Sharifi
NCT06764940 RECRUITING A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Biostar Pharma, Inc.
NCT07254858 NOT YET RECRUITING Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer
First Affiliated Hospital of Wenzhou Medical University
NCT04214288 ACTIVE NOT RECRUITING A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
AstraZeneca
NCT05867251 RECRUITING Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
NCT05607004 RECRUITING (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Atossa Therapeutics, Inc.
NCT06533826 RECRUITING TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Ana C Garrido-Castro, MD
NCT04230109 RECRUITING Sacituzumab Govitecan In TNBC
Massachusetts General Hospital
NCT04443348 ACTIVE NOT RECRUITING Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Laura M. Spring, MD
NCT06942234 RECRUITING Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT05582499 RECRUITING Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Fudan University
NCT06599216 ACTIVE NOT RECRUITING Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
Harbin Medical University
NCT07130643 ACTIVE NOT RECRUITING Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer
Xinhong Wu, PhD
NCT06874933 RECRUITING Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
First Affiliated Hospital of Zhejiang University
NCT06611813 RECRUITING Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
First Affiliated Hospital of Zhejiang University
NCT07113964 NOT YET RECRUITING QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
The First Affiliated Hospital with Nanjing Medical University
NCT07109284 NOT YET RECRUITING SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer
West China Hospital
NCT07101159 NOT YET RECRUITING Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Fujian Cancer Hospital
NCT06176261 RECRUITING DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Sarah Sammons, MD
NCT05275777 ACTIVE NOT RECRUITING A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
National University Hospital, Singapore
NCT06860529 RECRUITING Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Henan Cancer Hospital
NCT06568692 RECRUITING A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Processa Pharmaceuticals
NCT07005882 NOT YET RECRUITING Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy
Azienda Ospedaliero-Universitaria Careggi
NCT06964906 RECRUITING Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04802876 ACTIVE NOT RECRUITING Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
SOLTI Breast Cancer Research Group
NCT06839560 NOT YET RECRUITING Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients with Advanced HER2-Negative Breast Cancer with Brain Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT03989089 ACTIVE NOT RECRUITING Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
University of Malaya
NCT06516289 RECRUITING Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Fudan University
NCT06418594 RECRUITING Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Beijing 302 Hospital
NCT04985266 RECRUITING A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Royal Marsden NHS Foundation Trust
NCT06705127 RECRUITING Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
First Affiliated Hospital of Zhejiang University
NCT06102824 RECRUITING Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Guangdong Provincial People's Hospital
NCT06639672 NOT YET RECRUITING Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer
Lei Liu
NCT05594095 RECRUITING SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
NCT04282031 RECRUITING A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.
NCT06470633 NOT YET RECRUITING To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT06404463 NOT YET RECRUITING QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
Fudan University
NCT02315196 ACTIVE NOT RECRUITING Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Rutgers, The State University of New Jersey
NCT05576389 ENROLLING BY INVITATION Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer
Peking University People's Hospital
NCT04505826 COMPLETED A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
NCT05340413 COMPLETED Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.
SOLTI Breast Cancer Research Group
NCT05101564 COMPLETED Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Jennifer Lee Caswell-Jin
NCT05520723 COMPLETED Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED
MedSIR
NCT04504916 TERMINATED A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT05253053 COMPLETED To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT05054374 COMPLETED A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT01938833 TERMINATED Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01818063 COMPLETED Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04965688 TERMINATED Biology Guided Therapy for Breast Cancer for ER Positive
Inova Health Care Services
NCT04588298 COMPLETED A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
AstraZeneca
NCT03575065 COMPLETED Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
BeiGene
NCT05163106 COMPLETED Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
University Hospital, Akershus
NCT04738292 TERMINATED Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
University of Wisconsin, Madison
NCT04742959 COMPLETED Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT00618657 COMPLETED Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
University of California, Irvine
NCT00679029 TERMINATED Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
NCT04901299 WITHDRAWN Fulvestrant + Neratinib In Breast Cancer
Massachusetts General Hospital
NCT02983045 COMPLETED A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Nektar Therapeutics
NCT01234532 TERMINATED Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
University of Maryland, Baltimore
NCT05234606 WITHDRAWN A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Silverback Therapeutics
NCT02269670 TERMINATED Phase II Study of Everolimus Beyond Progression
Emory University
NCT01705691 COMPLETED Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NSABP Foundation Inc
NCT01037790 COMPLETED Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Abramson Cancer Center at Penn Medicine
NCT02015559 COMPLETED Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
Jonsson Comprehensive Cancer Center
NCT02983604 TERMINATED GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
Gilead Sciences
NCT01381874 COMPLETED A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Janssen Research & Development, LLC
NCT00733408 COMPLETED Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
University of Washington
NCT01151449 TERMINATED Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
National Cancer Institute (NCI)
NCT02685306 WITHDRAWN A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Peregrine Pharmaceuticals
NCT02273752 TERMINATED Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Emory University
NCT01368263 TERMINATED Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Washington University School of Medicine
NCT01329627 TERMINATED Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer
Instituto do Cancer do Estado de São Paulo
NCT01100489 WITHDRAWN Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
Case Comprehensive Cancer Center
